Clinical

NICE Guidelines on the use of Telbivudine and Entecavir for the Treatment of Hepatitis B

Telbivudine

Telbivudine (Sebivo, Novartis) is a synthetic thymidine nucleoside analogue. It works by inhibiting the viral DNA polymerase responsible for viral replication. Telbivudine is licensed for the treatment of chronic hepatitis B in adults with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

View information on NICE website

Word document iconDownload guidelines [138 Kb]

Entecavir

Entecavir (Baraclude, Bristol-Myers Squibb) is an oral nucleoside analogue. It works by inhibiting the viral DNA polymerase responsible for HBV replication. Entecavir has a marketing authorisation in the UK for the treatment of chronic HBV infection in adults with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. For further information, see the summary of product characteristics.

View information on NICE website

Word document iconDownload guidelines [143 Kb]